Shares of Eli Lilly and Company (LLY) gained on Monday morning after rival Novo Nordisk A/S reported that its next-generation obesity drug CagriSema underperformed Lilly's Zepbound in a head-to-head clinical trial.
The stock is currently trading at $1,059.41, up $49.89 or 4.94%, on the NYSE. The stock opened at $1,047.02 after closing at $1,009.52 on Friday. The stock has traded between $623.78 and $1,133.95 over the past 52 weeks.
Novo Nordisk said its experimental obesity treatment CagriSema did not match the weight-loss efficacy of Lilly's tirzepatide, sold as Zepbound in the U.S. and Mounjaro in Europe, in a late-stage trial.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.